<DOC>
	<DOCNO>NCT00753454</DOCNO>
	<brief_summary>The purpose study continue assess safety certolizumab pegol combination methotrexate ( MTX ) .</brief_summary>
	<brief_title>Open Label Extension Patients Coming From Dosing Flexibility Study Patients With Rheumatoid Arthritis ( RA )</brief_title>
	<detailed_description>Patients complete week 34 assessment C87077 ( NCT00580840 ) study meet pre-defined criterion flare ( defined patient randomize Week 18 experience 2 consecutive visit Week 18 Week 34 inclusive equal Baseline ( W0 ) bad swell tender joint count ) , give option enroll C87084 receive certolizumab pegol [ 400 mg Entry , Week 2 , Week 4 follow 200 mg every two week ( Q2W ) ] combination MTX drug commercially available indication Rheumatoid Arthritis ( RA ) patient 's country region notice UCB . All patient continue MTX treatment stable dose C87077 ( NCT00580840 ) study , unless need reduce dose reason toxicity .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Certolizumab Pegol</mesh_term>
	<criteria>Patients must able understand write Informed Consent Form ( ICF ) Patients must achieve ACR20 ( American College Rheumatology ) response Week 16 complete entire C87077 ( NCT00580840 ) study patient randomize Week 18 met predefined criterion flare Patients must comply protocol requirement participation C87077 ( NCT00580840 ) Female patient childbearing potential must negative urine pregnancy test Entry must continue negative urine pregnancy test throughout study participation Patients must willing comply protocol Patients must diagnosis inflammatory Arthritis Patients must secondary , noninflammatory type Arthritis investigator 's opinion symptomatic enough interfere evaluation study drug patient 's primary diagnosis Rheumatoid Arthritis ( RA ) Patients must history infect joint prosthesis prosthesis still situ Patients meet Medical History Exclusion criterion , define per protocol . Examples exclusionary criterion ( allinclusive ) : pregnancy , chronic infection , active Tuberculosis ( TB ) , high risk infection , Lymphproliferative Disorder , acute chronic Viral Hepatitis B C , know Human Immunodeficiency Virus ( HIV ) , Malignancy history Malignancy , history severe , progressive , and/or uncontrolled Renal , Hepatic , Hematological , Gastrointestinal , Endocrine , Pulmonary , Cardiac , Neurological Cerebral Disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>Joint Disease</keyword>
	<keyword>Arthritis</keyword>
	<keyword>Certolizumab pegol</keyword>
	<keyword>Cimzia</keyword>
</DOC>